Is GT Biopharma, Inc. overvalued or undervalued?

Jun 25 2025 08:15 AM IST
share
Share Via
As of October 5, 2023, GT Biopharma, Inc. is considered undervalued and attractive, with a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a return on equity of 12%, trading at a discount compared to peers like ImmunoGen and Novavax.
As of 5 October 2023, GT Biopharma, Inc. has moved from fair to attractive based on recent evaluations. The company is currently considered undervalued. Key ratios indicate a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a return on equity of 12%.

In comparison to its peers, such as ImmunoGen, Inc. with a price-to-earnings ratio of 20.5 and Novavax, Inc. at 18.3, GT Biopharma appears to be trading at a discount. This valuation is further supported by its recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of the current price point.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is GT Biopharma, Inc. technically bullish or bearish?
Jun 25 2025 08:15 AM IST
share
Share Via
What does GT Biopharma, Inc. do?
Jun 22 2025 06:03 PM IST
share
Share Via